Loading clinical trials...
Loading clinical trials...
A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris
Conditions
Interventions
CD5789 25 µg/g cream
CD5789 50 µg/g cream
+3 more
Locations
24
United States
Total Skin and Beauty Dermatology Center, PC
Birmingham, Alabama, United States
Parexel Early Phase
Glendale, California, United States
Odyssey Medispa
Marina del Rey, California, United States
Rady Children's Hospital
San Diego, California, United States
FXM Research Corp Miami
Miami, Florida, United States
FMX Research Miramar
Miramar, Florida, United States
Start Date
June 20, 2012
Primary Completion Date
July 24, 2013
Completion Date
June 12, 2014
Last Updated
September 20, 2021
NCT07205107
NCT06225570
NCT05891795
NCT06141330
NCT06501560
NCT03883269
Lead Sponsor
Galderma R&D
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions